Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gharda Chemicals Ltd...

    Gharda Chemicals Ltd to supply formulations to curb Zika Outbreak

    Written by savita thakur thakur Published On 2016-03-04T14:43:37+05:30  |  Updated On 4 March 2016 2:43 PM IST
    Gharda Chemicals Ltd to supply formulations to curb Zika Outbreak
    MUMBAI: With Zika being declared by WHO as a global threat, scientists across the world are working on curbing the spread of the dreaded virus - the latest to join the fray being Google, who has partnered with UNICEF to map the spread of the virus. In an important fillip to the 'Make in India' campaign, home-grown Gharda Chemicals Limited is steadily supplying WHO approved formulations to control the mosquito
    Aedes aegyptii
    which transmits the dreaded Zika virus, that has been rapidly spreading in South America and the Caribbean. The Zika virus is linked to an increase in the incidence of birth defects. With the first case being reported in Brazilin May 2015, the Zika virus could potentially infect 4 million people by the end of the year according to the WHO. The Aedes aegyptii also spreads dengue, yellow fever and chikungunya.

    A host of companies have announced their research on the Zika vaccine but experts believe that it could be years away. There is currently no cure or vaccine for the Zika virus. The management of the outbreak is currently focused on reducing the populations of the Aedes mosquito that carry the Zika virus.

    WHO recommends the following products manufactured by Gharda Chemicals Limited for the control of mosquito
    Aedes
    , both adults and larvae.

    For adult mosquitoes:

    - Deltamethrin EC, SC, WP, ULV, WG formulations

    - Alphacypermethrin SC and WP formulations

    For mosquito larvae in water bodies:

    - Temephos EC and GR formulations

    - Chlorpyrifos EC formulation

    Dr. K.N. Singh, Vice-President, Gharda Chemicals Limited said, "Gharda Chemicals can supply quality and effective products based on Deltamethrin, Alphacypermethrin, Chlorpyrifos and Temephos for the control of all types of mosquitoes viz.
    Aedes, Anapheles
    and Culex in its larval and adult stages to mitigate a global healthcare emergency."

    "Innovation combined with R&D has marked the rise of the company with many awards in the basket for process innovation and export performance," added Dr. Singh.

    Gharda Chemicals Limited has been steadily growing and has a strong presence across the globe. Besides being a winner of multiple awards; the Founder, Chairman and Managing Director of the company, Dr. Keki Hormusji Gharda has been honored by the Government of India with the prestigious Padma Shri.

    Aedes aegyptiiAlphacypermethrinChlorpyrifosDeltamethrinDr. K.N. SinghDr. Keki Hormusji GhardaGharda Chemicals LimitedNarendra ModiTemephosUNICEFWHOzika virus
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok